Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)
Journal
Future Oncology
Journal Volume
17
Journal Issue
32
Pages
4237-4247
Date Issued
2021
Author(s)
Abstract
NSCLC progressing on crizotinib to receive either brigatinib 180 mg qd (7-day lead-in at 90 mg qd) or alectinib 600 mg twice daily. The primary end point is progression-free survival as assessed by a blinded Independent Review Committee; the key secondary end point is overall survival. Clinical trial registration number: NCT03596866 (ClinicalTrials.gov).
SDGs
Publisher
Future Medicine Ltd.
Type
review